The long-term success of TechBio is dependent upon the flow of investment and alliances with mature life sciences companies. This collaborative model has proven many times over to be an ideal framework to develop new treatments for patients.
These are exciting times for the TechBio community, from the pioneering start-ups and academics to their industry partners and investors. Generative artificial intelligence has now become part of everyday conversation through the success of ChatGPT and other programs, raising awareness of some of the tools that underpin the technology aspect of TechBio companies.
Meanwhile, biotech drug pipelines are as deep as ever with the validation of new modalities and patient data being generated...
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
